Novavax Short

٣ نوفمبر ٢٠٢١

Pfizer's monopoly is very strong on the Covid-19 vaccines . They are spending millions hiding their side effects and creating hurdles for their competitors at the regulatory agencies SUCCESSFULLY . It maybe that Novavax has one the best products out there but that simply does not matter at this point , we know how powerful big pharma can be and Novavax's lateness to the game will not serve them well here . The biggest dangers to NVAX are now the regulatory agencies taking long/asking for additional info and the COVID-19 Antiviral drug news ( Merck's pill approval will be this months and Pfizer may come out with their Phase III study result any moment now). Both are very likely .

NVAX will likely reject braking $200 TODAY. $195 -$200 will be a great entry point for a opening a short position on this . RISK /REWARD RATIO VERY LUCRATIVE .